## IN THE CLAIMS:

Claim 17 is herein canceled. Claims 1 and 3 have been amended herein. All of the pending claims 1, 3, 6, 7, and 10 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

## **Listing of the Claims:**

- 1. (Currently amended) A peptide consisting of:
- the amino acid sequence of <u>SEQ ID NO:9</u> <u>SEQ ID NO:1</u> wherein <u>an original</u> the amino acid at position 2 thereof is <u>substituted with</u> valine and wherein said peptide is immunogenic with lymphocytes directed against metastatic melanomas.
  - 2. (Canceled).
- 3. (Withdrawn and Currently Amended) The peptide of claim 1, wherein the <u>original</u> amino acid at position 2, is <u>substituted by a replacement amino</u> acid selected from the group consisting of isoleucine, leucine, and valine.
  - 4.-5. (Canceled).
- 6. (Original) A vaccine comprising the peptide of claim 1 or a nucleotide sequence encoding said peptide.
- 7. (Original) The vaccine of claim 6, further comprising a pharmaceutically acceptable carrier or diluent.
  - 8.-9. (Canceled).

10. (Previously Presented) The vaccine of claim 6, characterized in that it further comprises one or more compounds selected from the group consisting of an adjuvant, one or more cytokines, antibodies directed against CD2, CD3, CD27, CD28 or other T cell surface antigens, and helper epitopes to stimulate CD4+ or CD8+ T cells.

11.-17. (Canceled).